Analysts Issue Forecasts for Zura Bio Limited’s FY2024 Earnings (NASDAQ:ZURA)

Zura Bio Limited (NASDAQ:ZURA) – Equities researchers at Cantor Fitzgerald issued their FY2024 earnings estimates for shares of Zura Bio in a research note issued on Wednesday, June 12th. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings of ($0.64) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Zura Bio’s current full-year earnings is ($0.53) per share.

Several other research firms have also weighed in on ZURA. Oppenheimer lifted their target price on shares of Zura Bio from $16.00 to $21.00 and gave the company an “outperform” rating in a report on Friday, May 10th. Piper Sandler initiated coverage on shares of Zura Bio in a report on Friday, May 3rd. They set an “overweight” rating and a $26.00 target price for the company. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $19.80.

Zura Bio Stock Up 1.1 %

NASDAQ:ZURA opened at $3.77 on Friday. The company has a 50 day moving average price of $4.34 and a 200-day moving average price of $3.98. Zura Bio has a 1-year low of $2.00 and a 1-year high of $13.00.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.21.

Insider Buying and Selling

In related news, Director Amit Munshi purchased 159,744 shares of the business’s stock in a transaction that occurred on Monday, April 22nd. The stock was bought at an average price of $3.13 per share, with a total value of $499,998.72. Following the acquisition, the director now owns 777,384 shares in the company, valued at $2,433,211.92. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Zura Bio news, Director Van Amstel Arnout Ploos bought 80,000 shares of the stock in a transaction on Friday, May 17th. The shares were bought at an average price of $6.20 per share, with a total value of $496,000.00. Following the purchase, the director now directly owns 100,000 shares in the company, valued at approximately $620,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Amit Munshi bought 159,744 shares of the stock in a transaction on Monday, April 22nd. The shares were acquired at an average cost of $3.13 per share, for a total transaction of $499,998.72. Following the purchase, the director now owns 777,384 shares in the company, valued at $2,433,211.92. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 250,926 shares of company stock valued at $1,030,998. 15.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Zura Bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in ZURA. Lynx1 Capital Management LP acquired a new stake in Zura Bio during the 3rd quarter worth $65,000. Forefront Analytics LLC boosted its stake in Zura Bio by 46.8% during the 4th quarter. Forefront Analytics LLC now owns 21,229 shares of the company’s stock worth $99,000 after purchasing an additional 6,765 shares during the last quarter. Eisler Capital US LLC acquired a new stake in Zura Bio during the 3rd quarter worth $660,000. Affinity Asset Advisors LLC acquired a new stake in Zura Bio during the 1st quarter worth $1,157,000. Finally, Silverarc Capital Management LLC boosted its stake in Zura Bio by 152.5% during the 3rd quarter. Silverarc Capital Management LLC now owns 404,040 shares of the company’s stock worth $2,667,000 after purchasing an additional 244,040 shares during the last quarter. Institutional investors and hedge funds own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.